Genus of bacteria
POPULARITY
4 episodes with Acinetobacter
2 episodes with Acinetobacter
3 episodes with Acinetobacter
2 episodes with Acinetobacter
2 episodes with Acinetobacter
3 episodes with Acinetobacter
2 episodes with Acinetobacter
2 episodes with Acinetobacter
2 episodes with Acinetobacter
Jonathan Stokes and his colleagues are discovering novel antibiotics through artificial intelligence (AI) - among others Halicin and Abaucin. This AI-driven research was named one of the years top discoveries by The New York Times in 2023. Stay tuned for a very futuristic - and inspiring - interview with a very interesting researcher!References: Swanson, K., Liu, G., Catacutan, D.B. et al. Generative AI for designing and validating easily synthesizable and structurally novel antibiotics. Nat Mach Intell 6, 338–353 (2024).Lluka T, Stokes JM. Antibiotic discovery in the artificial intelligence era. Ann N Y Acad Sci. 2023 Jan;1519(1):74-93. doi: Liu G, Catacutan DB, Rathod K, Swanson K, Jin W, Mohammed JC, et al. Deep learning-guided discovery of an antibiotic targeting Acinetobacter baumannii. Nature Chemical Biology. 2023;19(11):1342-50.Stokes JM, Yang K, Swanson K, Jin W, Cubillos-Ruiz A, Donghia NM, et al. A Deep Learning Approach to Antibiotic Discovery. Cell. 2020;180(4):688-702.e13. Awan RE, Zainab S, Yousuf FJ, Mughal S. AI-driven drug discovery: Exploring Abaucin as a promising treatment against multidrug-resistant Acinetobacter baumannii. Health Sci Rep. 2024;7(6):e2150. Higashihira S, Simpson SJ, Morita A, Suryavanshi JR, Arnold CJ, Natoli RM, Greenfield EM. Halicin remains active against Staphylococcus aureus in biofilms grown on orthopaedically relevant substrates. Bone Joint Res. 2024 Mar 4;13(3):101-109. doi: 10.1302/2046-3758.133.BJR-2023-0038.R2. PMID: 38432258; PMCID: PMC10909403. Hosted on Acast. See acast.com/privacy for more information.
Dies ist der zweite Teil über multiresistente Erreger, die wir anhand der IDSA Guidance on the Treatment of Antimicrobial Resitant Gram-Negativ Infections besprechen. Dieses Mal geht es um Pseudomonas aeruginosa, Acinetobacter baumanii und Stenotrophomonas maltophilia. Wir erklären die unterscheidlichen Resistenzmechanismen, diskutieren deren Folgen und Therapiemöglichkeiten. Links: IDSA Guidance on the Treatment of Antimicrobial Resistant Gram-Negativ … „Infektiopod #87: Multiresistente gramnegative Erreger – Teil 2“ weiterlesen
Carbapenemase producers are a nightmare for clinicians. Not only are they resistant to carbapenems, a last resort β-lactam antibiotic, they are notorious for developing multidrug and pandrug resistances resulting in limited to no treatment options. In this episode of Communicable, hosts Angela Huttner and Thomas Tängdén sit down with Dr. David Paterson (National University of Singapore) and Dr. Souha Kanj (American University of Beirut Medical Center, Lebanon), two ID physicians from regions where carbapenem-resistant Enterobacteriaceae or CRE, and carbapenem-resistant Acinetobacter are widespread. The episode begins with the history and emergence of CRE and reviews current epidemiology, diagnosis (including the Ambler classification of β-lactamases) and treatment options. Lessons and insights from personal experiences are shared to reflect the current clinical challenges caused by carbapenem-resistant bacteria and the importance of infection prevention and control measures to mitigate further spread. This episode was edited by Kathryn Hostettler and peer-reviewed by Dr. Filippo Medioli of Policlinico di Modena, Italy. For more related content on the WHO Priority Pathogens List and new antibiotics in the pipeline, check out our previous episodes, Communicable E3 and E10 (see Literature).Literature Communicable E3 - The New WHO Priority Pathogens List: which bugs to target first? June 2024. https://communicable.transistor.fm/episodes/communicable-e3-the-new-who-priority-pathogens-list-which-bacteria-to-target-first Communicable E10 - Pipeline update: new antibiotics & other antimicrobials that you might actually use. Sep 2024. https://communicable.transistor.fm/episodes/communicable-e10-pipeline-update-new-antibiotics-other-antimicrobials-that-you-might-actually-use Wagenlehner FM, et al. Cefepime-Taniborbactam in Complicated Urinary Tract Infection. N Engl J Med 2024 Feb. doi: 10.1056/NEJMoa2304748 Cohn J, et al. Accelerating antibiotic access and stewardship: a new model to safeguard public health. Lancet Infect Dis 2024 Sep. doi: 10.1016/S1473-3099(24)00070-7 Timsit JF, et al. When should I start broad-spectrum antibiotics? Intensive Care Med 2024 Sep. doi: 10.1007/s00134-024-07654-7 Paterson DL. Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials. Expert Opin Investig Drugs 2024 Apr. doi: 10.1080/13543784.2024.2326028
On the verge of a post-antibiotic reality, there is an urgent clinical need for new antibiotics. Luckily, new candidates are in the pipeline and older agents are getting a second breath of life through combination therapy. In this episode of Communicable, host Erin McCreary invites Dr. Markus Zeitlinger of the University of Vienna (Austria) and scientific expert for the European Medicines Agency (EMA) and Dr. Michael Dudley, president and CEO of Qpex Biopharma, to discuss antimicrobials in the clinical development pipeline. Together they unpack how the WHO curate the priority list of pathogens and how companies adapt such lists into their antimicrobial development business plans. They also discuss the unique challenges and complexities of developing antibiotics, from return on investments and defining the ‘novelty' of an agent to the conundrum of balancing post-market approval and antimicrobial stewardship. Beta-lactamase inhibitors and oral carbapenems in the pipeline targeting ‘the big three' (Enterobacterales, Pseudomonas and Acinetobacter) are the primary focus. This episode was edited by Kathryn Hostettler and peer-reviewed by Dr. Benjamin Berinson of the Medical Centre Hamburg-Eppendorf (UKE), Germany. For more information on the WHO Priority Pathogens List and its 2024 update, check out our previous episode, Communicable E3 (see Literature). Literature Communicable E3 - The New WHO Priority Pathogens List: which bugs to target first? 17 June 2024. https://communicable.transistor.fm/episodes/communicable-e3-the-new-who-priority-pathogens-list-which-bacteria-to-target-first WHO Bacterial Priority Pathogens List, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. Geneva: World Health Organization; 17 May 2024. https://www.who.int/publications/i/item/9789240093461 C. Le Terrier et al, NDM-9 resistance to taniborbactam. Lancet Infect Dis 23, 401-402 (2023). doi 10.1016/S1473-3099(23)00069-5 P. B. Eckburg et al, Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection. N Engl J Med 386, 1327-1338 (2022). doi: 10.1056/NEJMoa2105462 A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) (PIVOT-PO). https://clinicaltrials.gov/study/NCT06059846 Meiji Seika Pharma Initiated the Global Phase III Clinical Trials of OP0595, a Novel beta-Lactamase Inhibitor for Combatting Antimicrobial Resistance (AMR). Tokyo: Meiji Seika Pharma Ltd; 26 April 2023. https://www.meiji.com/global/news/2023/pdf/230426_01.pdf
O Acinetobacter sp. resistente a carbapênemicos, ou CRAB (Carbapenem-resistant A. baumannii), é uma das bactérias de mais difícil manejo devido as resistências antimicrobianas. Nesse Ep. William e Lino conversam sobre as recomedações atuais de tratamento na realidade local. ref. https://www.idsociety.org/practice-guideline/amr-guidance/.
Drs. Yohei Doi and Emily Heil join Dr. Erin McCreary to dive into one of the most requested topics from our listeners and something that is consistently confusing in clinical practice: Acinetobacter baumannii! Hear from experts on their experience with treating this tricky organism and their thoughts on best approaches when you are presented with CRAB. Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/ References: SNAP doi:10.1128/mbio.02759-2 ATTACK doi:10.1016/S1473-3099(23)00184-6 CRAB among COVID patients: doi:10.1093/jac/dkad042
In this episode Brett, Phil and Martin tour the posters at ESCMID Global 2024 and we discuss some of them with the authors. A link to images of the posters can be found below. Here are the posters we discuss AMR Surveillance in waste water and clinical isolates from a tertiary hospital: Preliminary results Deciphering the temporal short-term dynamics of Acinetobacter baumanii: Impact of colonisation pressure in infection in an endemic Indian intensive care unit (Manasa Tantry discussion) Post-antibiotic risk for recurrent lower respiratory tract infection during prolonged hospitalisation Transmission of MDRO during physical and occupational therapy appointmants a 3 Veterans Affairs Hospitals Aircraft lavatory wastewater surveillance for SARS-CoV2 and other coronaviruses by using family-wide RT-PCR, Thailand, October – November 2023 Enhancing feedback and implementation of infection risk scan findings (IRIS) among healthcare workers in nursing homes Proper glove use: a multicentre before-after regional study (Anne F. Voor and Juliëtte Severin discussion) Poster link to see the posters we discuss Posters from ESCMID Global - Part 1 More posters to come!
In this episode Brett, Phil and Martin tour the posters at ESCMID Global 2024 and we discuss some of them with the authors. A link to images of the posters can be found below. Here are the posters we discuss AMR Surveillance in waste water and clinical isolates from a tertiary hospital: Preliminary results Deciphering the temporal short-term dynamics of Acinetobacter baumanii: Impact of colonisation pressure in infection in an endemic Indian intensive care unit (Manasa Tantry discussion) Post-antibiotic risk for recurrent lower respiratory tract infection during prolonged hospitalisation Transmission of MDRO during physical and occupational therapy appointmants a 3 Veterans Affairs Hospitals Aircraft lavatory wastewater surveillance for SARS-CoV2 and other coronaviruses by using family-wide RT-PCR, Thailand, October – November 2023 Enhancing feedback and implementation of infection risk scan findings (IRIS) among healthcare workers in nursing homes Proper glove use: a multicentre before-after regional study (Anne F. Voor and Juliëtte Severin discussion) Poster link to see the posters we discuss Posters from ESCMID Global - Part 1 More posters to come!
Scientists from Stanford Medicine and McMaster University have developed an artificial intelligence model called SyntheMol that has generated structures and chemical recipes for six novel drugs to combat antibiotic-resistant strains of Acinetobacter baumannii bacteria. This bacterium is responsible for many antibiotic resistance-related deaths. The model was trained to construct potential drugs using a library of over 130,000 molecular building blocks and a set of validated chemical reactions. Out of the 58 compounds that were successfully generated and tested in the lab, six of them proved effective against A. baumannii and other antibiotic-resistant bacteria. The researchers plan to further test the compounds for toxicity and collaborate with other research groups for drug discovery in different areas. --- Send in a voice message: https://podcasters.spotify.com/pod/show/tonyphoang/message
El catedrático de Veterinaria, Christian de la Fe, explica los avances publicados en Nature por científicos de la empresa Roche. Han desarrollado la zosurabalpina, capaz de superar la resistencia de una de las bacterias que más preocupan, la Acinetobacter baumannii.
In the second of three episodes, listen to Dr. Fatimah Alshahrani and Dr. Abdullah Almohaizeie discuss carbapenem-resistance Acinetobacter!Episodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.com
In this episode, Emily Heil, PharmD, MS, BCIDP, AAHIVP; Laila Woc-Colburn, MD; and Trevor Van Schooneveld, MD, FSHEA, FACP, discuss their approach to managing infections involving carbapenem-resistant Acinetobacter baumannii (CRAB), including: Mechanisms for β-lactam resistanceAdditional resistance mechanisms and virulence factors2023 IDSA guidance recommendations for moderate to severe CRAB infectionsThe latest clinical data by antimicrobial therapy/regimen:SulbactamMeropenem and colistinCarbapenem, sulbactam, and polymyxin BTetracyclinesCefiderocolSulbactam/durlobactam and carbapenems Program Director:Trevor Van Schooneveld, MD, FSHEA, FACP Professor, Division of Infectious DiseasesProgram Director, Infectious Diseases FellowshipMedical Director, Antimicrobial Stewardship ProgramUniversity of Nebraska Medical CenterOmaha, NebraskaFaculty:Emily Heil, PharmD, MS, BCIDP, AAHIVPAssociate ProfessorDepartment of PharmacyUniversity of Maryland School of PharmacyID Clinical Pharmacy SpecialistUniversity of Maryland Medical CenterBaltimore, MarylandLaila Woc-Colburn, MDAssociate ProfessorDivision of Infectious DiseasesEmory University School of Medicine Atlanta, GeorgiaContent based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Follow along with a downloadable slideset at: https://bit.ly/476v2wILink to full program: https://bit.ly/40Mmicz
Ready for some startling Steno statistics? In this big 1-parter, Callum & Jame go through Stenotrophomonas maltophilia, from start to finish. Unlike Pseudomonas & Acinetobacter, Steno is much less commonly seen outside of ITU & the immunocompromised; but when it shows up you have to know what you're doing. Luckily for you, there's basically only 2 treatments! (In Europe: you'll see what I mean).2 crap puns in this one, so… get ready for that. Support the showQuestions, comments, suggestions to idiotspodcasting@gmail.com or on X/Threads @IDiots_podPrep notes for completed episodes can be found here (Not all episodes have prep notes).If you are enjoying the podcast please leave a review on your preferred podcast app!Feel like giving back? Donations of caffeine gratefully received!https://www.buymeacoffee.com/idiotspod
In Part 2 of our episodes on Acinetobacter we talk abouit resistance, and then do a deep dive into the evidence base for the management of CRAB: Carbapenem-Resistant Acinetobacter Baumanii-calcoaceticus complex. Do have a look at the prep notes for this episode if you want more information on Acinetobacter. Links to podcasts mentioned in this episodeID:IOTS Episode 41: Bugs Without BordersFebrile episodes 76 & 77: Piece de (Gram-negative) ResistanceEpisode 76Episode 77For links to the papers we used, see the prep notes! Support the showQuestions, comments, suggestions to idiotspodcasting@gmail.com or on X/Threads @IDiots_podPrep notes for completed episodes can be found here (Not all episodes have prep notes).If you are enjoying the podcast please leave a review on your preferred podcast app!Feel like giving back? Donations of caffeine gratefully received!https://www.buymeacoffee.com/idiotspod
In this episode, Callum and Jame go over the second big family of nonfermentors, Acinetobacter. In part 1 we talk about the organisms themselves, risk factors, clinical syndromes and diagnostics before talking a little about treatment. In Part 2 (released next week) we'll talk about Carbapenem-Resistant Acinetobacter Baumanii-calcoaceticus (CRAB), and resistance mechanisms in general. Support the showQuestions, comments, suggestions to idiotspodcasting@gmail.com or on X/Threads @IDiots_podPrep notes for completed episodes can be found here (Not all episodes have prep notes).If you are enjoying the podcast please leave a review on your preferred podcast app!Feel like giving back? Donations of caffeine gratefully received!https://www.buymeacoffee.com/idiotspod
Univ.-Prof. Dr. Robert Krause und Univ.-Prof. Dr. Florian Thalhammer diskutieren über Acinetobacter bis Stenotrophomonas. Die Aufzeichnung fand im Zuge unseres Giftigen Live Streams am 11. Juli 2023 statt.
Ethiker*innen blicken mit Sorge auf die rasante Entwicklung in der KI-Forschung - in manchen Bereichen aber auch mit Gelassenheit. Denn man muss zwischen verschiedenen Dimensionen von künstlicher Intelligenz unterscheiden, und die sind mit ganz unterschiedlichen Risiken behaftet. Bislang regulieren KI-Entwickler sich höchstens selbst, und das soll zunächst auch so bleiben. Doch im Alltag steckt viel mehr KI, als das vielen bewusst ist. Deshalb mahnt die Forschung eine Regulation an, wie die EU sie jetzt auf den Weg bringen will. Das gilt auch für das menschliche Feedback, mit dem Anwendungen und Algorithmen optimiert werden sollen - und hier besteht noch immer eine regulatorische Lücke. Frederik Schulz-Greve hat mit Wissenschaftler*innen gesprochen, die sich mit den ethischen Grundlagen und Folgen der Anwendung von Künstlicher Intelligenz beschäftigen. Im Gespräch mit Host Lucie Kluth erklärt er, wo Potenziale liegen, warum Hochschulen auch angstbefreit an den Umgang mit ChatGPT herangehen könnten, wie Crowdworker Feedback geben und was all das zum Beispiel mit der Entwicklung von Antibiotika zu tun hat. Die Hintergrundinformationen: Stellungnahme des Deutschen Ethikrats zum Thema Künstliche Intelligenz (KI): Deutscher Ethikrat. Mensch und Maschine – Herausforderungen durch Künstliche Intelligenz. https://www.ethikrat.org/publikationen/publikationsdetail/?tx_wwt3shop_detail%5Bproduct%5D=168&tx_wwt3shop_detail%5Baction%5D=index&tx_wwt3shop_detail%5Bcontroller%5D=Products&cHash=2832da3eabd1b566403727910cee637e [aufgerufen am 22. Juni 2023] Nvidia über Wettervorhersage mithilfe von KI: Nvidia. Stormy Weather? Scientist Sharpens Forecasts With AI. Nvidia Blog. https://blogs.nvidia.com/blog/2022/11/01/ai-weather-forecasts-durran/ [aufgerufen am 22. Juni 2023] Studie über Bauchspeicheldrüsenkrebsforschung mithilfe von KI: Placido D et al. A deep learning algorithm to predict risk of pancreatic cancer from disease trajectories. Nature Medicine. 2023;29: 1113-1122. https://doi.org/10.1038/s41591-023-02332-5 Informationen zur Häufigkeit von Bauchspeicheldrüsenkrebs in Deutschland: Zentrum für Krebsregisterdaten. Bauchspeicheldrüsenkrebs (Pankreaskarzinom). https://www.krebsdaten.de/Krebs/DE/Content/Krebsarten/Bauchspeicheldruesenkrebs/bauchspeicheldruesenkrebs_node.html [aufgerufen am 22. Juni 2023] Studie zur Krankenhauskeimforschung mithilfe von KI: Liu G et al. Deep learning-guided discovery of an antibiotic targeting Acinetobacter baumannii. Nature Chemical Biology. 2023. https://doi.org/10.1038/s41589-023-01349-8 Informationen über die Projekte von Professor Bela Gipp: https://gipplab.org/projects/ [aufgerufen am 22. Juni 2023] Deutschlandfunkbeitrag über KI in chinesischen Schulen: DLF: Alles unter Kontrolle - Chinas intelligenter Schule entgeht nichts. https://www.deutschlandfunk.de/alles-unter-kontrolle-chinas-intelligenter-schule-entgeht-102.html [aufgerufen am 22. Juni 2023] Studie des DIW zu KI im Arbeitsumfeld: Giering O et al. Künstliche Intelligenz in Deutschland: Erwerbstätige wissen oft nicht, dass sie mit KI-basierten Systemen arbeiten. DIW Wochenbericht 2021;48. https://www.diw.de/documents/publikationen/73/diw_01.c.830715.de/21-48-1.pdf [aufgerufen am 22. Juni 2023] Nicht begutachtete Analyse der Entwickler:innen von ChatGPT zu den Auswirkungen von KI auf den Arbeitsmarkt: Eloundou T et al. GPTs are GPTs: An Early Look at the Labor Market Impact Potential of Large Language Models. Working paper; 2023. https://arxiv.org/pdf/2303.10130.pdf [aufgerufen am 22. Juni 2023] Analyse von Goldman Sachs zu den Auswirkungen von KI auf den Arbeitsmarkt: Hatzius J et al: Global Economics Analyst - The Potentially Large Effects of Artificial Intelligence on Economic Growth. Goldman Sachs – Economics Research; 2023. https://www.gspublishing.com/content/research/en/reports/2023/03/27/d64e052b-0f6e-45d7-967b-d7be35fabd16.html [aufgerufen am 22. Juni 2023] Studie zu den Effekten von KI auf den chinesischen Arbeitsmarkt: Zhou G et al. The effect of artificial intelligence on China's labor market. China Economic Journal. 2020; 13(1), 24-41. https://doi.org/10.1080/17538963.2019.1681201 Weitere Informationen zu Auswirkungen von KI auf den Arbeitsmarkt: KI und Arbeitsmarkt: Welche Effekte sind zu erwarten? Science Media Center. https://www.sciencemediacenter.de/alle-angebote/science-response/details/news/ki-und-arbeitsmarkt-welche-effekte-sind-zu-erwarten/[aufgerufen am 22. Juni 2023] EU-KI-Verordnung - Gesetzesvorschlag der EU-Kommission: EUR-Lex. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A52021PC0206 [aufgerufen am 22. Juni 2023] Informationen zur KI-Verordnung für Unternehmen von einer Anwaltskanzlei: Die KI-Verordnung kommt. Leitfaden für Unternehmen. Schürmann Rosenthal Dreyer. https://www.srd-rechtsanwaelte.de/ki-verordnung/ [aufgerufen am 22. Juni 2023] Informationen über geheilten Querschnittsgelähmten: Lorach H et al. Walking naturally after spinal cord injury using a brain-spine interface. Nature. 2023;618: 126-133. https://doi.org/10.1038/s41586-023-06094-5 Studie von Paul Rainey zum Thema KI und Evolution: Rainey P. Major evolutionary transitions in individuality between humans and AI. Philosophical Transactions of the Royal Society B – Biological Sciences. 2023;378. https://doi.org/10.1098/rstb.2021.0408
Ethiker*innen blicken mit Sorge auf die rasante Entwicklung in der KI-Forschung - in manchen Bereichen aber auch mit Gelassenheit. Denn man muss zwischen verschiedenen Dimensionen von künstlicher Intelligenz unterscheiden, und die sind mit ganz unterschiedlichen Risiken behaftet. Bislang regulieren KI-Entwickler sich höchstens selbst, und das soll zunächst auch so bleiben. Doch im Alltag steckt viel mehr KI, als das vielen bewusst ist. Deshalb mahnt die Forschung eine Regulation an, wie die EU sie jetzt auf den Weg bringen will. Das gilt auch für das menschliche Feedback, mit dem Anwendungen und Algorithmen optimiert werden sollen - und hier besteht noch immer eine regulatorische Lücke. Frederik Schulz-Greve hat mit Wissenschaftler*innen gesprochen, die sich mit den ethischen Grundlagen und Folgen der Anwendung von Künstlicher Intelligenz beschäftigen. Im Gespräch mit Host Lucie Kluth erklärt er, wo Potenziale liegen, warum Hochschulen auch angstbefreit an den Umgang mit ChatGPT herangehen könnten, wie Crowdworker Feedback geben und was all das zum Beispiel mit der Entwicklung von Antibiotika zu tun hat. Die Hintergrundinformationen: Stellungnahme des Deutschen Ethikrats zum Thema Künstliche Intelligenz (KI): Deutscher Ethikrat. Mensch und Maschine – Herausforderungen durch Künstliche Intelligenz. https://www.ethikrat.org/publikationen/publikationsdetail/?tx_wwt3shop_detail%5Bproduct%5D=168&tx_wwt3shop_detail%5Baction%5D=index&tx_wwt3shop_detail%5Bcontroller%5D=Products&cHash=2832da3eabd1b566403727910cee637e [aufgerufen am 22. Juni 2023] Nvidia über Wettervorhersage mithilfe von KI: Nvidia. Stormy Weather? Scientist Sharpens Forecasts With AI. Nvidia Blog. https://blogs.nvidia.com/blog/2022/11/01/ai-weather-forecasts-durran/ [aufgerufen am 22. Juni 2023] Studie über Bauchspeicheldrüsenkrebsforschung mithilfe von KI: Placido D et al. A deep learning algorithm to predict risk of pancreatic cancer from disease trajectories. Nature Medicine. 2023;29: 1113-1122. https://doi.org/10.1038/s41591-023-02332-5 Informationen zur Häufigkeit von Bauchspeicheldrüsenkrebs in Deutschland: Zentrum für Krebsregisterdaten. Bauchspeicheldrüsenkrebs (Pankreaskarzinom). https://www.krebsdaten.de/Krebs/DE/Content/Krebsarten/Bauchspeicheldruesenkrebs/bauchspeicheldruesenkrebs_node.html [aufgerufen am 22. Juni 2023] Studie zur Krankenhauskeimforschung mithilfe von KI: Liu G et al. Deep learning-guided discovery of an antibiotic targeting Acinetobacter baumannii. Nature Chemical Biology. 2023. https://doi.org/10.1038/s41589-023-01349-8 Informationen über die Projekte von Professor Bela Gipp: https://gipplab.org/projects/ [aufgerufen am 22. Juni 2023] Deutschlandfunkbeitrag über KI in chinesischen Schulen: DLF: Alles unter Kontrolle - Chinas intelligenter Schule entgeht nichts. https://www.deutschlandfunk.de/alles-unter-kontrolle-chinas-intelligenter-schule-entgeht-102.html [aufgerufen am 22. Juni 2023] Studie des DIW zu KI im Arbeitsumfeld: Giering O et al. Künstliche Intelligenz in Deutschland: Erwerbstätige wissen oft nicht, dass sie mit KI-basierten Systemen arbeiten. DIW Wochenbericht 2021;48. https://www.diw.de/documents/publikationen/73/diw_01.c.830715.de/21-48-1.pdf [aufgerufen am 22. Juni 2023] Nicht begutachtete Analyse der Entwickler:innen von ChatGPT zu den Auswirkungen von KI auf den Arbeitsmarkt: Eloundou T et al. GPTs are GPTs: An Early Look at the Labor Market Impact Potential of Large Language Models. Working paper; 2023. https://arxiv.org/pdf/2303.10130.pdf [aufgerufen am 22. Juni 2023] Analyse von Goldman Sachs zu den Auswirkungen von KI auf den Arbeitsmarkt: Hatzius J et al: Global Economics Analyst - The Potentially Large Effects of Artificial Intelligence on Economic Growth. Goldman Sachs – Economics Research; 2023. https://www.gspublishing.com/content/research/en/reports/2023/03/27/d64e052b-0f6e-45d7-967b-d7be35fabd16.html [aufgerufen am 22. Juni 2023] Studie zu den Effekten von KI auf den chinesischen Arbeitsmarkt: Zhou G et al. The effect of artificial intelligence on China's labor market. China Economic Journal. 2020; 13(1), 24-41. https://doi.org/10.1080/17538963.2019.1681201 Weitere Informationen zu Auswirkungen von KI auf den Arbeitsmarkt: KI und Arbeitsmarkt: Welche Effekte sind zu erwarten? Science Media Center. https://www.sciencemediacenter.de/alle-angebote/science-response/details/news/ki-und-arbeitsmarkt-welche-effekte-sind-zu-erwarten/[aufgerufen am 22. Juni 2023] EU-KI-Verordnung - Gesetzesvorschlag der EU-Kommission: EUR-Lex. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A52021PC0206 [aufgerufen am 22. Juni 2023] Informationen zur KI-Verordnung für Unternehmen von einer Anwaltskanzlei: Die KI-Verordnung kommt. Leitfaden für Unternehmen. Schürmann Rosenthal Dreyer. https://www.srd-rechtsanwaelte.de/ki-verordnung/ [aufgerufen am 22. Juni 2023] Informationen über geheilten Querschnittsgelähmten: Lorach H et al. Walking naturally after spinal cord injury using a brain-spine interface. Nature. 2023;618: 126-133. https://doi.org/10.1038/s41586-023-06094-5 Studie von Paul Rainey zum Thema KI und Evolution: Rainey P. Major evolutionary transitions in individuality between humans and AI. Philosophical Transactions of the Royal Society B – Biological Sciences. 2023;378. https://doi.org/10.1098/rstb.2021.0408
June comes with a bang! Tune in to this episode to hear the insights of the incomparable Dame Sally Davies, former UK Chief Medical Officer and current UK Special Envoy on Antimicrobial Resistance. We chat with her about her path to being a global advocate on AMR, the need for better global governance, and what her vast experience has taught her. Talking to her was a truly inspirational experience. In the news section, we bring you a very cool article using deep learning and computational methods (hello Artificial Intelligence!) to find a potential antibiotic against Acinetobacter baumanii, and a brief study presenting the results of a new antimicrobial susceptibility testing that is independent of growth by analyzing bacterial nano-movement Check relevant links in the show notes at http://www.uac.uu.se/the-amr-studio/episode49. Follow our updates on twitter on http://www.twitter.com/uac_uu with #theAMRstudio hashtag! Theme music by Henrik Niss: http://www.tinyurl.com/henriknissspotify.
This episode, we're bringing to light how researchers have identified a potent drug that specifically targets the dangerous drug-resistant bacteria, Acinetobacter baumannii, known for causing infections in hospital settings.We'll discuss how this antibiotic was not only effective against the superbug in mice studies but also showed promising results against 41 different strains of an antibiotic-resistant virus. The unique aspect of this antibiotic is its narrowly targeted action that leaves beneficial bacteria unharmed, potentially preventing resistance development.The journey of discovery doesn't stop there; the researchers also successfully deployed artificial intelligence in a novel approach to drug discovery, significantly reducing the time required to sift through thousands of potential compounds. Is AI the next frontier in drug discovery?Finally, we'll take you through the intriguing story of the antibiotic's development, originally considered for treating diabetes. Join us as we explore the wonders of AI in healthcare, the potential future of antibiotics, and what this could mean for tackling the growing issue of antibiotic resistance.Support the showLet's get into it!Follow us!Email us: TheCatchupCast@Gmail.com
Podcast jest dostępny także w formie newslettera: https://ainewsletter.integratedaisolutions.com/ Naukowcy z MIT i McMaster University wykorzystali algorytm sztucznej inteligencji do zidentyfikowania nowego antybiotyku, który może zabić Acinetobacter baumannii, rodzaj bakterii odpowiedzialny za wiele infekcji lekoopornych.https://news.mit.edu/2023/using-ai-scientists-combat-drug-resistant-infections-0525 Naukowcy z University College London zidentyfikowali pięć podtypów niewydolności serca, które można wykorzystać do przewidywania przyszłego ryzyka dla poszczególnych pacjentów.https://medicalxpress.com/news/2023-05-heart-failure-ai-tools.html Firma Google DeepMind opublikowała artykuł badawczy przedstawiający system porównawczy do ilościowego określania wydajności czworonożnych robotów.https://techcrunch.com/2023/05/30/google-deepmind-introduces-barkour-a-benchmark-for-quadrupedal-robots/ National Eating Disorders Association (NEDA) zwolniło swoich pracowników infolinii i zastąpiło ich chatbotem o nazwie Tessa, zaledwie cztery dni po związkach zawodowych pracowników.https://futurism.com/eating-disorder-hotline-staff-chatbot Odwiedź www.integratedaisolutions.com
Forscher am MIT und an der McMaster University haben mithilfe eines Algorithmus der künstlichen Intelligenz ein neues Antibiotikum identifiziert, das Acinetobacter baumannii abtöten kann, eine Bakterienart, die für viele arzneimittelresistente Infektionen verantwortlich ist.https://news.mit.edu/2023/using-ai-scientists-combat-drug-resistant-infections-0525 Forscher des University College London haben fünf Subtypen der Herzinsuffizienz identifiziert, die zur Vorhersage des zukünftigen Risikos für einzelne Patienten herangezogen werden könnten.https://medicalxpress.com/news/2023-05-heart-failure-ai-tools.html DeepMind von Google hat ein Forschungspapier herausgegeben, in dem ein Benchmarking-System zur Quantifizierung der Leistung von vierbeinigen Robotern beschrieben wird.https://techcrunch.com/2023/05/30/google-deepmind-introduces-barkour-a-benchmark-for-quadrupedal-robots/ Die National Eating Disorders Association (NEDA) hat ihre Hotline-Mitarbeiter entlassen und sie durch einen Chatbot namens Tessa ersetzt, nur vier Tage nachdem sich die Arbeiter gewerkschaftlich organisiert hatten.https://futurism.com/eating-disorder-hotline-staff-chatbot Visit www.integratedaisolutions.com
Researchers at MIT and McMaster University have used an artificial intelligence algorithm to identify a new antibiotic that can kill Acinetobacter baumannii, a type of bacteria that is responsible for many drug-resistant infections.https://news.mit.edu/2023/using-ai-scientists-combat-drug-resistant-infections-0525 Researchers at University College London have identified five subtypes of heart failure that could be used to predict future risk for individual patients.https://medicalxpress.com/news/2023-05-heart-failure-ai-tools.html Google's DeepMind has issued a research paper outlining a benchmarking system to quantify the performance of quadruped robots.https://techcrunch.com/2023/05/30/google-deepmind-introduces-barkour-a-benchmark-for-quadrupedal-robots/ The National Eating Disorders Association (NEDA) has fired its hotline staff and replaced them with a chatbot called Tessa, just four days after the workers unionized.https://futurism.com/eating-disorder-hotline-staff-chatbot Visit www.integratedaisolutions.com
AI Chat: ChatGPT & AI News, Artificial Intelligence, OpenAI, Machine Learning
Leveraging the power of artificial intelligence, scientists from McMaster University and the Massachusetts Institute of Technology have successfully identified a new antibiotic capable of combatting the dangerous superbug, Acinetobacter baumannii. As revealed in a study published in Nature Chemical Biology, the AI model was trained and deployed to analyze 6,680 unexplored compounds, which resulted in the discovery of nine potential antibiotics, including one named abaucin. Subsequent testing on a wound infection model in mice showed abaucin effectively suppressing the infection, thereby marking a promising stride in the use of machine learning for antibiotic discovery. Download Selfpause the AI Life Coach: https://Selfpause.com/AIBox Get our Daily AI Newsletter: https://AIBox.ai Join our ChatGPT Community: https://www.facebook.com/groups/739308654562189/ Follow me on Twitter: https://twitter.com/jaeden_ai
Get our free download! Implementing AMA Style – 8 Things to Get Right In this episode, we discuss the latest FDA approvals from May 22 to May 26, 2023. Here are the key highlights: Inpefa (sotagliflozin) has received FDA approval as a once-daily oral tablet for reducing the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus. Common side effects include urinary tract infection, volume depletion, diarrhea, and hypoglycemia. Paxlovid, a combination of nirmatrelvir and ritonavir tablets, has been granted full approval as an oral antiviral treatment for adults with mild-to-moderate COVID-19 at high risk for severe illness. Clinical data suggests significant risk reduction in hospitalizations and deaths with Paxlovid use. Neuralink, founded by Elon Musk, has received FDA approval for its brain implant called "The Link." This brain-computer interface aims to help patients with severe paralysis regain the ability to control external technologies using neural signals. Xacduro (sulbactam/durlobactam injection) has been approved for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii–calcoaceticus complex. Xacduro is the first pathogen-targeted therapy approved for this type of pneumonia. Brixadi (buprenorphine) Extended-Release Subcutaneous Injection has received FDA approval for the treatment of moderate-to-severe opioid use disorder. It is available in weekly and monthly injection formulations and should be used as part of a comprehensive treatment plan. Opvee, the first nalmefene hydrochloride nasal spray, has been approved for the emergency treatment of known or suspected opioid overdose in adults and pediatric patients. Nalmefene is an opioid receptor antagonist that can reverse the effects of opioid overdose if administered quickly. Listen to all the episodes here. Also brought to you by Nascentmc.com. A group of MD- and PhD-level medical writers serving the continuing medical education industry and meeting medical writing deadlines with excellence and enthusiasm. Intro and outro musicGarden Of Love by Pk jazz Collective
In this episode, Marion Elligsen, BScPhm, MSc, RPh, ACPR; Keith S Kaye, MD, MPH; and Andrew Shorr, MD, MPH, MBA, discuss key considerations for selecting empiric antibiotic regimens in patients with HABP/VABP in the intensive care unit, including: The role of novel β-lactam/β-lactamase inhibitor combinationsUse of clinical predictions scores (eg, Drug Resistance in Pneumonia [DRIP] score) to predict risk for pneumonia caused by multidrug-resistant pathogensApplication of rapid diagnostic testing in critically ill patients with pneumonia, including current limitationsImplementation of advanced antibiograms and clinical prediction scoresClinical utility of biomarkers for pneumonia (eg, procalcitonin)Application of updated nosocomial pneumonia classifications in clinical practiceFaculty:Marion Elligsen, BScPhm, MSc, RPh, ACPRPractice-Based ResearcherSunnybrook Research InstituteAntimicrobial Stewardship Pharmacy LeadDepartment of PharmacySunnybrook Health Sciences CentreToronto, Ontario, CanadaKeith S. Kaye, MD, MPHChief Division of Allergy, Immunology and Infectious DiseasesProfessor of MedicineRutgers Robert Wood Johnson Medical SchoolNew Brunswick, New JerseyAndrew Shorr, MD, MPH, MBADirectorPulmonary and Critical Care MedicineMedstar Washington Hospital CenterWashington, DCContent based on a CME program supported by an educational grant from Merck Sharp & Dohme Corp. Link to full program:https://bit.ly/3HaZpYwLink to downloadable slideset:https://bit.ly/3UxHoqr
The antibiotic resistant bacteria contracted in hospital now linked to covid Website: www.Kevinstew.com I DO NOT OWN THE RIGHTS TO ANY MUSIC USED. FOR PROMOTIONAL PURPOSES ONLY. All Featured Content Is Monetized By The Respective Copyright Owners & Record Labels. FAIR USE DISCLAIMER: I do not own copyright for this copyrighted material, but under Section 107 United States Copyright Law as noted by the United States Copyright Office (Copyright Act 1976), allowance is made for fair use for purposes such as criticism, comment, news reporting, teaching, scholarship, and research. I state here in a good faith that I have made and uploaded here this copy of this copyrighted material completely for the purposes of comment and criticism - i.e. my production of the copy of this copyrighted material and sharing of it here on this podcast in this particular case - is totally non-profit, and that I believe that my production of this copy of this copyrighted material and sharing of it here in this podcast in this particular case can only increase value of this copyrighted material and produce only positive effects for this copyrighted material in its potential market. --- Support this podcast: https://anchor.fm/djkevinstew/support
Join Jame and Callum and they discuss some of the other Enterobacterales Gram negatives. Particularly breaking down them into their families and into Lactose fermenters and non-fermenters. Jame has a small breakdown around our Twitter handle near the end.Comments suggestions and criticisms to idiotspodcasting@gmail.com or @IDiots_pod Some lists:Chromosomal AmpC Carriers (high-risk): HECK YES· Hafnia alvei, Enterobacter cloacae, Citrobacter freundii, Klebsiella aerogenes, Yersinia enterocoliticaLower Risk Chromosomal AMPC: Vulgar Providencia Store AMPC· Proteus Vulgaris, Providencia, Serratia, Acinetobacter, Morganella, Providencia Intrinsic Colistin Resistance: · Burkholderia cepacia (Nonfermenter), Proteus, Providencia, Serratia Biochemical mimics of Salmonella (also can group)· Hafnia, Morganella,Proteus Cat 3 organisms: · Salmonella typhi/paratyphi, Shigella dysenteriae type 1, E.coli O157, Yersinia PestisSome useful resources:SMI ID 16: identification of Enterobacteriaceaehttps://www.gov.uk/government/publications/smi-id-16-identification-of-enterobacteriaceae Janda JM, Abbott SL. 2021. The changing face of the family Enterobacteriaceae (order: “Enterobacterales”): new members, taxonomic issues, geographic expansion, and new diseases and disease syndromes. Clin Microbiol Rev 34:e00174-20. https://doi.org/10.1128/CMR.00174-20
In this week's episode, Brett and Martin talk to Adjunct Assistant Prof Dr Kalisvar Marimuthu, who is currently a senior consultant in Infectious Diseases at the National Centre for Infectious Diseases and Tan Tock Seng Hospital, Singapore. We discuss his recent paper that notes that over 50% of transmissions occurring in healthcare result from plasmid and not colonal spread. Traditional IPC interventions seem to work for clonal transmission, however new thinking is required to tackle the problems of plasmids. Papers we discuss are: 1. Marimuthu K, Venkatachalam I, Koh V et al. Whole genome sequencing reveals hidden transmission of carbapenemase-producing Enterobacterales. Nat Commun 2022; 13: 3052. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160272/ 2. Ng DHL, Marimuthu K, Lee JJ et al. Environmental colonization and onward clonal transmission of carbapenem-resistant Acinetobacter baumannii (CRAB) in a medical intensive care unit: the case for environmental hygiene. Antimicrob Resist Infect Control 2018; 7: 51. https://aricjournal.biomedcentral.com/articles/10.1186/s13756-018-0343-z
In this week's episode, Brett and Martin talk to Adjunct Assistant Prof Dr Kalisvar Marimuthu, who is currently a senior consultant in Infectious Diseases at the National Centre for Infectious Diseases and Tan Tock Seng Hospital, Singapore. We discuss his recent paper that notes that over 50% of transmissions occurring in healthcare result from plasmid and not colonal spread. Traditional IPC interventions seem to work for clonal transmission, however new thinking is required to tackle the problems of plasmids. Papers we discuss are: 1. Marimuthu K, Venkatachalam I, Koh V et al. Whole genome sequencing reveals hidden transmission of carbapenemase-producing Enterobacterales. Nat Commun 2022; 13: 3052. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160272/ 2. Ng DHL, Marimuthu K, Lee JJ et al. Environmental colonization and onward clonal transmission of carbapenem-resistant Acinetobacter baumannii (CRAB) in a medical intensive care unit: the case for environmental hygiene. Antimicrob Resist Infect Control 2018; 7: 51. https://aricjournal.biomedcentral.com/articles/10.1186/s13756-018-0343-z
Wound Healing Accelerated with Topical DIM The phytochemical 3,3'-diindolylmethane (DIM) successfully broke down the biofilms protecting two different pathogens including Acinetobacter baumannii and pseudomonas aeruginosa– enabling their eradication 65% and 70% of the time, respectively. Combined with antibiotics, that number jumped to 94%. Golberg K, Markus V, Kagan B-e, Barzanizan S, Yaniv K, Teralı K, Kramarsky-Winter E, Marks RS, Kushmaro A. Anti-Virulence Activity of 3,3′-Diindolylmethane (DIM): A Bioactive Cruciferous Phytochemical with Accelerated Wound Healing Benefits. Pharmaceutics. 2022; 14(5):967. https://doi.org/10.3390/pharmaceutics14050967 #DIM #wounds #healing #ulcers DIM, Wounds, Healing, ULCERS, BIOFILM, P. aeruginosa , Pseudomonas aeruginosa, Gram-negative pathogens, Phytochemicals, Antimicrobial , Acinetobacter baumannii, hospital infections, battlefield infections, A. baumannii, Diindolylmethane, acne, candida DIM, Wounds, Healing, ULCERS, BIOFILM, P. aeruginosa , Pseudomonas aeruginosa, Gram-negative pathogens, Phytochemicals, Antimicrobial , Acinetobacter baumannii, hospital infections, battlefield infections, A. baumannii, Diindolylmethane, acne, candida --- Support this podcast: https://anchor.fm/ralph-turchiano/support
Wound Healing Accelerated with Topical DIM The phytochemical 3,3'-diindolylmethane (DIM) successfully broke down the biofilms protecting two different pathogens including Acinetobacter baumannii and pseudomonas aeruginosa– enabling their eradication 65% and 70% of the time, respectively. Combined with antibiotics, that number jumped to 94%. Golberg K, Markus V, Kagan B-e, Barzanizan S, Yaniv K, Teralı K, Kramarsky-Winter E, Marks RS, Kushmaro A. Anti-Virulence Activity of 3,3′-Diindolylmethane (DIM): A Bioactive Cruciferous Phytochemical with Accelerated Wound Healing Benefits. Pharmaceutics. 2022; 14(5):967. https://doi.org/10.3390/pharmaceutics14050967 #DIM #wounds #healing #ulcers DIM, Wounds, Healing, ULCERS, BIOFILM, P. aeruginosa , Pseudomonas aeruginosa, Gram-negative pathogens, Phytochemicals, Antimicrobial , Acinetobacter baumannii, hospital infections, battlefield infections, A. baumannii, Diindolylmethane, acne, candida --- Support this podcast: https://anchor.fm/ralph-turchiano/support
We are joined again by Prof Mark Pallen who takes us through his early experiences in high-throughput microbial genomics. Mark was pleased that he persuaded Nick Loman to join him in Birmingham. Mark tells us how they worked with George Weinstock to perform the first genome sequence analyses of Gram-negatives for genomic epidemiology—in this case of multi-drug resistant Acinetobacter baumannii. After winning an Ion Torrent sequencer in a competition, Mark and Nick then contributed some pioneering genomic analyses of the German STEC outbreak. One of their studies involved crowd sourced approaches, primed by Twitter and was published in the New England Journal of Medicine; the other provided a performance comparison of newly launched bench top sequencing platforms. Mark, Lee and Nabil discuss how this outbreak overturned dogmas concerning the archetypal status of pathotypes of E. coli. The conversation then moves on to the need for evidence trails and challenging assumptions, whether annotating proteins or quoting Darwin (see https://colinpurrington.com/2012/02/darwin-on-the-floor-lhao/). Nabil recalls the excitement of realtime analysis of an epidemic and acknowledges the legacy of Mark and Nick's work in 2011 to current approaches to the Covid pandemic. Mark describes his exciting experiences exploiting metagenomics in clinical and ancient DNA contexts, including analysis of disease-associated stool samples and of 200-year TB genomes in Hungarian mummies. Yet again this led to overturning of assumptions--in this case that people only get infected with a single strain of M. tuberculosis. It turns out that multiple infections were the norm 200 years ago. Shortly afterwards, Pallen helped assemble a team that analysed undersea sediments shedding light on the Neolithic transition in England and culminating in a Science paper. Mark then takes us through his recent metagenomics analyses of critically ill patients and of the chicken gut, emphasising the excitement of finding hundreds of new species in such a commonplace setting. Mark finishes off by sharing his excitement that there is still so much of the microbial world left for us to discover using sequencing and bioinformatics analyses. We are just 2% of the way there!
American Journal of Infection Control: Science Into Practice
Tune in to hear our hosts Nicki Shorr and Jessie Swain talk with infection preventionists Rachel Guran and Kelsi Canavan along with Dr. Paula Eckardt about containing a carbapenem-resistant Acinetobacter baumannii complex outbreak in a COVID-19 intensive care unit. With special guests: Rachel Guran, MPH, BSN, RN, CIC, Kelsi Canavan, MPH, MPA, CIC and Paula A. Eckardt, MD, FACP, FIDSA, AAHIVS
HelixTalk - Rosalind Franklin University's College of Pharmacy Podcast
In this episode, we discuss six newer antibiotics that target multidrug resistant gram negative bacteria with Dr. Christie Bertram, PharmD, BCIDP. We review common resistance mechanisms, particularly to carbapenems, and highlight the current role in therapy for the following antibiotics: ceftolozane/tazobactam (Zerbaxa®), ceftazidime/avibactam (Avycaz®), meropenem/vaborbactam (Vabomere®), imipenem/cilastatin/relebactam (Recarbrio®), cefiderocol (Fetroja®), and eravacycline (Xerava®). Key Concepts Ceftolozane/tazobactam (Zerbaxa®) is primarily used for multidrug resistant Pseudomonas; it does not cover carbapenemase-producing organisms and (despite the tazobactam) needs metronidazole for intra-abdominal anaerobic coverage. Ceftazidime/avibactam (Avycaz®) is primarily used to cover CRE (Carbapenem-resistant Enterobacterales) but also has activity for many other gram negatives except Acinetobacter. Meropenem/vaborbactam (Vabomere®) has similar coverage to Avycaz® but may provide coverage for certain KPCs (Klebsiella pneumoniae carbapenemase). Vaborbactam does not restore activity for meropenem-resistant Pseudomonas. Imipenem/cilastatin/relebactam (Recarbrio®) has similar coverage to Avycaz® and Vabomere®; true niche in therapy is not yet well defined. Cefiderocol (Fetroja®) uses a unique mechanism to enter gram negative bacteria and has a broad spectrum of activity against carbapenemase-producing bacteria and many other multidrug resistant gram negatives. It has no gram positive activity. Eravacycline (Xerava®) is a tigecycline-like tetracycline with a broad spectrum of activity against carbapenemase-producing gram negative, gram positive, an anaerobic bacteria EXCEPT it lacks coverage for Pseudomonas. References Yusuf E, Bax HI, Verkaik NJ, van Westreenen M. An Update on Eight "New" Antibiotics against Multidrug-Resistant Gram-Negative Bacteria. J Clin Med. 2021;10(5):1068. Published 2021 Mar 4. doi:10.3390/jcm10051068 CDC Antibiotic Resistance Threats in the United States, 2019 report. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf
How do bacteriophages shape bacterial fitness and how does it lead to the resensitiization of antimicrobials? In today's show, we are delighted to have Dr. Jeremy Barr from Monash University to talk about his research and his recent republication on Nature Microbiology "Bacteriophage-resistant Acinetobacter baumannii are resensitized to antimicrobials". Maybe it's time for us to have a better understanding of the key pathogens' cellular biology and defense mechanisms to combat the challenge of AMR. You can find the article @https://www.nature.com/articles/s41564-020-00830-7 and find out more about Dr. Barr's research @https://scholar.google.com/citations?user=Ebx3KmEAAAAJ&hl=en Find out about Australia's collaborative effort on phage therapy @ https://phageaustralia.org
In this episode, Keith S. Kaye, MD, MPH; Lilian Abbo, MD, FIDSA; and Jason M. Pogue, PharmD, discuss HABP/VABP and gram-negative resistance including:Epidemiology and burden of nosocomial bacterial pneumoniaPatient-specific risk factors for MDR pathogensImproving outcomes with the use of antibiogramsRecommended empiric therapy for clinically suspected VABPAntimicrobial resistance in HABP/VABPAlgorithms for gram-negative organism antibiotic-susceptibility testingUsing rapid diagnostic tests for HABP/VABPNew antimicrobial agents for MDR gram-negative infections with discussion of the 2021 IDSA guidance, and the following studies:ASPECT-NP: ceftolozane/tazobactam vs meropenemREPROVE: ceftazidime/avibactam vs meropenemRESTORE-IMI-1 imipenem/cilastatin/relebactam vs colistin + imipenemRESTORE-IMI-2: imipenem/cilastatin/relebactam vs piperacillin/tazobactamAPEKS-NP: cefiderocol vs meropenemCREDIBLE-CR: cefiderocol vs best available therapyProgram Director:Keith S. Kaye, MD, MPHChiefDivision of Allergy, Immunology and Infectious DiseasesProfessor of MedicineRutgers Robert Wood Johnson Medical SchoolNew Brunswick, New JerseyFaculty:Lilian Abbo, MD, FIDSAAssociate Chief Medical Officer in Infectious DiseasesJackson Health SystemProfessor of Infectious DiseasesDepartment of Medicine & Miami Transplant InstituteUniversity of Miami Miller School of MedicineMiami, FloridaJason M. Pogue, PharmDClinical ProfessorDepartment of Clinical PharmacyUniversity of Michigan College of PharmacyInfectious Diseases Clinical PharmacistMichigan MedicineAnn Arbor, MichiganContent based on a CME program supported by an educational grant from Merck Sharp & Dohme Corp.Follow along with a downloadable slideset at:https://bit.ly/3CEop6hLink to full program https://bit.ly/3i781lf
Drs. Pranita Tamma (@pranita_tamma) and Sam Aitken (@OncIDPharmd) are BACK on the podcast this week with Dr. Erin McCreary (@ErinMcCreary) to discuss IDSA guidance on AmpC producers, carbapenem-resistant Acinetobacter baumanii, and Stenotrophomonas as part of our series on gram-negative bacteria. Listen as the panelists navigate the hot mess that is the CRAB treatment landscape, have a minocycline appreciation moment (we stan for Steno Sam!), and throw down some bar trivia in an "I Feel Nerdy" segment that you don't want to miss. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ References Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa) - PubMed (nih.gov) Infectious Diseases Society of America Guidance on the Treatment of AmpC β-lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections - PubMed (nih.gov) An Overview of the Treatment of Less Common Non-Lactose-Fermenting Gram-Negative Bacteria Alterations of the Oral Microbiome and Cumulative Carbapenem Exposure Are Associated With Stenotrophomonas maltophilia Infection in Patients With Acute Myeloid Leukemia Receiving Chemotherapy
Infections caused by carbapenem-resistant Acinetobacter spp. are considered an urgent public health problem. Antibiotic options are scarce but new drugs may be available in the near future. We discuss this important topic with experts in the field. Topics discussed: Acinetobacter as an opportunistic pathogen Therapeutic approaches for Acinetobacter infections The future approach for this MDR organisms. Guests: Dr. Yohei Doi, Professor and Director, Center for Innovative Antimicrobial Therapy, University of Pittsburgh Medical Center, Pittsburgh, PA Dr. Joseph Patrick Hornak. Fellow, Infectious Diseases, University of Texas Medical Branch, Galveston, TX
Cathal Friel, Co-Founder & Chairman & Jeremy Skillington, CEO of Poolbeg Pharma #POLB discuss the Option Agreement they signed with University College Dublin for a Melioidosis Vaccine candidate, MelioVac, and a licence to evaluate 5 other infectious disease portfolio assets. Highlights Poolbeg Pharma , a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has signed an Option Agreement to licence MelioVac, a vaccine for melioidosis, with University College Dublin ('UCD') and its inventor, Associate Professor Siobhán McClean, through NovaUCD, the university's knowledge transfer office. The Company will continue its due diligence on MelioVac, a preclinical asset and recipient of a Wellcome Trust Award to aid its development, as well as 5 of other potential vaccine candidates discovered by Associate Professor McClean and her team, for the duration of the Option Agreement, prior to signing a 'Licence Agreement'. Dr McClean is Associate Professor and Head of Biochemistry at the UCD School of Biomolecular and Biomedical Science. Dr McClean completed her BSc in Biochemistry in UCD and received her PhD from Imperial College London. Her research focuses on lung infections which led her to develop a platform technology to identify proteins that bacteria use to attach to human cells. These proteins have proved to be excellent vaccine candidates. Dr McClean completed some of the original research to identify the antigens associated with the Melioidosis Vaccine at TU Dublin. Poolbeg Pharma has identified melioidosis as an infectious disease of interest due to its rising incidence around the world and because there is currently no approved vaccine available. Concerns are growing about global warming contributing to the spread of the disease to traditionally non-tropical areas. Melioidosis, also known as Whitmore's disease, is an infectious disease caused by the bacterium Burkholderia pseudomallei, commonly found in the soil and surface groundwater of many tropical and subtropical regions, with diverse clinical presentations including pneumonia and severe sepsis with multiple organ abscesses. Incidence of the disease is widespread in South-East Asia, Northern Australia and India, with climate change having a substantial impact on the spread of the disease to new areas such as Brazil. There are an estimated 165,000 cases of melioidosis each year, of which as many as 89,000 (54%) are estimated to be fatal. Other potential vaccine candidates that the Company is evaluating include those for Klebsiella pneumoniae, Escherichia coli (O157), Burkholderia cepacia complex, Pseudomonas aeruginosa and Acinetobacter baumannii. About Poolbeg Pharma Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company, with a capital light clinical model which aims to develop multiple products faster and more cost effectively than the conventional biotech model. The Company, headquartered in London, is led by a team with a track record of creation and delivery of shareholder value and aspires to become a "one-stop shop" for Big Pharma seeking mid-stage products to licence or acquire. The Company is targeting the growing infectious disease market. In the wake of the COVID-19 pandemic, infectious disease has become one of the fastest growing pharma markets and is expected to exceed $250bn by 2025. With its initial assets from Open Orphan plc, an industry leading infectious disease and human challenge trials business, Poolbeg has access to knowledge, experience, and clinical data from over 20 years of human challenge trials. The Company is using these insights to acquire new assets as well as reposition clinical stage products, reducing spend and risk. It already has a Phase II ready repositioned small molecule immunomodulator for severe influenza and a portfolio of other exciting assets. The Company plans to broaden this portfolio further going forward and is in active discussions with AI data analysis platforms to help accelerate the power of its human challenge model data and biobank.
Brady MF, Jamal Z, Pervin N. Acinetobacter. [Actualizado el 13 de agosto de 2021]. En: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 enero-. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK430784/ --- Send in a voice message: https://anchor.fm/las-poderosas-celulas-nk/message
Baquero-Marín PJ, Cabarcas-López WF, Carrillo-Betancourt PX, Gaviria-Maya JE, Giraldo-Ospina B, Barrios-Arroyave FA. Infección urinaria por Acinetobacter baumannii adquirida en la comunidad: caso clínico de una paciente embarazada. Ginecol Obstet Mex. 2018 octubre;86(10):682-686. --- Send in a voice message: https://anchor.fm/las-poderosas-celulas-nk/message
El tratamiento antibiótico empírico debe basarse en el diagnóstico clínico, el tiempo transcurrido entre el ingreso del paciente al hospital y el diagnóstico de sepsis y los datos epidemiológicos locales de sensibilidad antimicrobiana (neumonía adquirida en la comunidad, neumonía asociada a la atención médica). En pacientes con infección por covid. Los gérmenes aislados son: En las primeras dos semanas de infección por covid: Streptococcus pneumoniae, Streptococcus agalactiae Agalctie, Streptococcus viridans Después de las dos semanas de infección por covid: Aumenta la incidencia de gram negativos fermentadores como la Klebsiella pneumoniae, Enterobacter cloacae enterobacter cloacae, Enterobacter aerogenes y no fermentadores como la Pseudomonas aeruginosa, Acinetobacter baumannii, stenotropona maltofiala y algunas formas Micoticas como Candida albicans y no albicans La mayoría de gérmenes aislados en UCI covid son gram negativos por causa de la translocación bacteriana. Antibióticos usados en hospitalizados por infección por covid: Betalactámicos de tercera generación como ceftriaxona y si hay factores de riesgo cefepime. No usar meropenem, no imipenem, no doripenem, no piperacilina tazobactam, no vancomicina (a no ser en casos puntuales). Si la infección bacteriana en pacientes hospitalizados por infección por covid es por un gram positivo tipo Staphylococcus aureus sensible a la meticilína, colocamos oxacilina en infusión continua dosis total/día en infusión para 24 horas . Ojo no abusar de antibióticos. Pacientes con infección leve o moderada con negatividad de procalcitonina no antibióticos Antibióticos dejarlos para los pacientes hipotensos, con procalcitonina positiva y con cambios radiográficos evidentes. Siempre hemocultivar y si salen negativos retirar antibióticos al 4 o 5 día, cuando salga el reporte ______________________________________________________ REFERENCIA https://www.minsalud.gov.co/salud/publica/PET/Documents/MEDICAMENTOS%20ESCENCIALES-UCI-COVID-19%20final-25-marzo.pdf ADAPTACION PARA AUDIO-OYENTES: Medicina en una página. ==================================================== PODCAST CORONAVIRUS. COVID-19 Este es un podcast en el que desde el ojo de la ciencia. Aprenderemos del coronavirus y de la enfermedad covid-19. Recuerden al enemigo es mejor conocerlo. Para acabarlo. Esta es una producción de: Medicina en una página. medicinaenunapagina@gmail.com Dirección y Conducción: John Jarbis García Tamayo. Médico y cirujano, Epidemiólogo y Pedagogo Universitario. Portada: Gracias a Sam Balye por compartir su trabajo (foto-portada) en https://unsplash.com/. Música: https://www.youtube.com/audiolibrary/music?nv=1
Em seis anos de estudos, foram obtidos resultados satisfatórios com o emprego de bactérias Acinetobacter sp como degradadora de herbicidas. Presentes no solo, essas bactérias se alimentam dos pesticidas que vão se depositando. Uma parceria da Agência Radioweb e da Agência Pública.
Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.09.01.278697v1?rss=1 Authors: Grinter, R., Morris, F. C., Dunstan, R. A., Leung, P. M., Belousoff, M., Gunasinghe, S. D., Beckham, S., Peleg, A. Y., Greening, C., Li, J., Heinz, E., Lithgow, T. Abstract: Acinetobacter baumannii is a high-risk pathogen due to the rapid global spread of multi-drug resistant lineages. Its phylogenetic divergence from other ESKAPE pathogens means that determinants of its antimicrobial resistance can be difficult to extrapolate from other widely studied bacteria. A recent study showed that A. baumannii upregulates production of an outer-membrane lipoprotein, which we designate BonA, in response to challenge with polymyxins. Here we show that BonA has limited sequence similarity and distinct structural features compared to lipoproteins from other bacterial species. Analyses through X-ray crystallography, small-angle X-ray scattering, electron microscopy, and multiangle light scattering demonstrate that BonA has a dual BON-domain architecture and forms a decamer via an unusual oligomerization mechanism. This analysis also indicates this decamer is transient, suggesting dynamic oligomerization plays a role in BonA function. Antisera recognizing BonA shows it is an outer membrane protein localized to the divisome. Loss of BonA modulates the density of the outer membrane, consistent with a change in its structure or link to the peptidoglycan, and prevents motility in a clinical strain (ATCC 17978). Consistent with these findings, the dimensions of the BonA decamer are sufficient to permeate the peptidoglycan layer, with the potential to form a membrane-spanning complex during cell division. Copy rights belong to original authors. Visit the link for more info
Professor Liz Harry is Professor of Biology and previously the Director of the ithree institute (infection, immunology and innovation) at the University of Technology, Sydney (UTS).Liz obtained her PhD in Biochemistry from the University of Sydney. She then went to Harvard University as a National Institutes of Health (NIH, USA) Postdoctoral Fellow. There she pioneered the development of fluorescence microscopy techniques for bacteria that enabled visualization of the subcellular proteins inside bacterial cells. These techniques have revolutionized our view of the internal organization of bacterial cells. They revealed that bacterial cells are highly organized, with proteins having specific cellular addresses that are exquisitely controlled in time and space.Liz then returned to Australia to be an Australian Research Council (ARC) Postdoctoral Fellow and then an ARC QEII Fellow in the School of Molecular Biosciences at the University of Sydney. She was then head-hunted to take up a position as Associate Professor at the ithree institute (then known as the Institute for the Biotechnology of Infectious Diseases) with the aim of building a team of bacterial biologists. She was promoted to Professor of Biology in 2010, and has played a leading role in the recruitment of several eminent Australian and international researchers to the institute.Professor Harry's research on bacterial cell division has had a significant impact on our understanding of how bacterial cells multiply, and how they control this process to ensure equal partitioning of chromosomes vital for survival. Her research has often changed the direction of thinking in the field, and has afforded excellent opportunities in antibacterial discovery. Her cutting-edge cell biology techniques including super resolution microscopy have provided unique insights in the mechanism and spatiotemporal control of the division process in bacteria. She made the surprising discovery that the cytokinetic ring, which is a polymer of the tubulin-like protein, FtsZ, forms at the division site at midcell as a result of the remodeling of a cytoskeletal helical assembly of polymers. Her research has shown that this Z ring is linked to the progress of the initiation phase of DNA replication, and gave rise to a new definition for the role of long-known sptatial regulators of bacterial division.With the move to the ithree institute, CI Harry shifted some of her fundamental research focus on bacterial cell division toward bacteria that cause infectious disease, such as Staphylococcus aureus and Acinetobacter baumannii, and antibacterial discovery. Professor Harry has worked with industry in antibacterial discovery research for the development of novel antibiotics that target this process in pathogens, and to examine how natural products function as effective therapeutics for infectious disease.Liz was awarded the 2002 Australian Eureka Prize for Scientific Research, and recently won the 2008 ASM Frank Fenner Award, awarded by the Australian Society for Microbiology in recognition of her distinguished contributions to Australian research in microbiology. She has had several Plenary invitations to international conferences and served on the Executive of the Australian Society for Microbiology for several years. She is currently a member of the Australian Academy of Science, National Committee for Biomedical Sciences.
Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.08.02.233189v1?rss=1 Authors: Vollmer, W., Hernandez-Rocamora, V. M., Baranova, N., Peters, K., Breukink, E., Loose, M. Abstract: Peptidoglycan is an essential component of the bacterial cell envelope that surrounds the cytoplasmic membrane to protect the cell from osmotic lysis. Important antibiotics such as {beta}-lactams and glycopeptides target peptidoglycan biosynthesis. Class A penicillin binding proteins are bifunctional membrane-bound peptidoglycan synthases that polymerize glycan chains and connect adjacent stem peptides by transpeptidation. How these enzymes work in their physiological membrane environment is poorly understood. Here we developed a novel FRET-based assay to follow in real time both reactions of class A PBPs reconstituted in liposomes or supported lipid bilayers and we demonstrate this assay with PBP1B homologues from Escherichia coli, Pseudomonas aeruginosa and Acinetobacter baumannii in the presence or absence of their cognate lipoprotein activator. Our assay allows unravelling the mechanisms of peptidoglycan synthesis in a lipid-bilayer environment and can be further developed to be used for high throughput screening for new antimicrobials. Copy rights belong to original authors. Visit the link for more info
While on a bucket list trip to Egypt, Steffanie Strathdee's husband Tom Patterson fell ill with what they first assumed to be food poisoning. They soon discovered it was much more serious. Tom was diagnosed with pancreatitis and gallstones. The gallstones had blocked his biliary duct, which had caused an abscess the size of a small football to form in his abdomen. When the fluid inside the abscess was cultured, doctors found the “worst bacteria on the planet,” Acinetobacter baumannii. This bacteria, nicknamed Iraqibacter due to the veterans who have returned from the middle east with the superbug, is an organism that is very prone to acquiring antimicrobial resistance genes from other bacteria. Tom was very ill. With the combination of pancreatitis and the superbug, his chance of survival was no more than 10%. Acinetobacter baumannii was only partially sensitive to three known antibiotics, and those were considered to be last chance therapies. He was treated with those drugs, but his bacteria resisted all of them. Steffanie is an infectious disease epidemiologist, but felt blindsided by Tom's diagnosis. Luckily, she had the right combination of knowledge, access to research, and willing medical and research professionals to try alternative therapies. Her research led her to phage therapy. Bacteriophage therapy (phage therapy, for short), are viruses that have naturally evolved to attack bacteria. The perfect predator, they have been co-evolving with bacteria for 4 billion years. There are more than 10 million trillion trillion phages on earth and they are everywhere: in water, soil, and our bodies. Phage therapy has been a known treatment against bacteria for decades, but has been practiced more in the former Soviet Union since western countries started relying on penicillin and other antibiotics since the 1940's. The challenge is to find the particular phage that is effective against the bacterial infection being treated. You are going to love this story of love, determination, resourcefulness and triumph. Steffanie cured Tom's illness with the help of three universities, the US Navy and researchers from across the world. What she discovered in the process is a super weapon against multidrug antimicrobial resistant diseases, which are expected to kill more than ten million people per year by 2050. Links and notes: Steffanie Strathdee and Robert Schooley are co-directors of the Center for Innovative Phage Applications and Therapeutics (“IPATH”) at UC San Diego Donate to IPATH here Steffanie Strathdee and Tom Patterson's book about their ordeal is called The Perfect Predator Learn more about The Infection Prevention Strategy at ic.tips If you liked this podcast, please consider subscribing to the series and leaving a positive review
Bacteria are becoming increasingly resistant to many of the agents we use to deal with them, including antiseptics. The bacterium Acinetobacter baumannii is one example and causes hard to treat skin, chest, and urine infections in hospitals. Now, a team at the University of Newcastle, Australia have discovered a gene that renders Acinetobacter resistant to the chemical chlorhexidine that's used in hand disinfectants. But the gene evolved long before the antiseptic was invented, so what was it doing previously? As well as finding out, Adam Murphy also heard from lead author Karl Hassan how the... Like this podcast? Please help us by supporting the Naked Scientists
Bacteria are becoming increasingly resistant to many of the agents we use to deal with them, including antiseptics. The bacterium Acinetobacter baumannii is one example and causes hard to treat skin, chest, and urine infections in hospitals. Now, a team at the University of Newcastle, Australia have discovered a gene that renders Acinetobacter resistant to the chemical chlorhexidine that's used in hand disinfectants. But the gene evolved long before the antiseptic was invented, so what was it doing previously? As well as finding out, Adam Murphy also heard from lead author Karl Hassan how the... Like this podcast? Please help us by supporting the Naked Scientists
Nie očkovanie nespôsobuje autizmus. To je jedno z najväčších klamstiev dnešných šíriteľov pavedeckých nezmyslov. No čosi autizmus predsa len spôsobuje. A zdá sa, že vedci teraz narazili na stopy mechanizmu, ktorého výsledkom môžu byť poruchy autistického spektra – aspoň u mužov. A výskumníci tiež zrejme rozlúštili záhadu rádioaktívneho mraku nad Európu z roku 2017. A pravdepodobne našli aj miesto, odkiaľ únik pochádzal. Tento týždeň budeme v podcaste ZOOM hľadať príčinu autizmu a zistíme, odkiaľ pred dvomi rokmi prišiel rádioaktívny oblak nad Európu či aké planéty našli v kozme astronómovia. Krátke správy z vedy Nová chemická látka sa osvedčila pri boji s odolnými baktériami. Vedci vytvorili antimikrobiálny peptid, ktorý vyskúšali na multirezistentnej baktérii Acinetobacter baumannii. Mikrób je na vrchu rebríčka hrozieb Svetovej zdravotníckej organizácie , ktorá hovorí o akútnej potrebe nových antibiotík proti tejto baktérii. Výskum naznačuje, že Mesiac môže byť starší, než sme si dosiaľ mysleli. Analýza chemického zloženia rôznych mesačných kúskov nazbieraných počas misií Apollo ukázala, že Mesiac vznikol už 50 miliónov rokov po sformovaní sa slnečnej sústavy. Dosiaľ sme si mysleli, že to bolo o 100 miliónov rokov neskôr. Vedci vyvinuli kontaktnú šošovku, ktorá sa dá ovládať pohybom oka. Ak človek dvakrát zažmurká, šošovka mu priblíži scénu, na ktorú sa pozerá. Technológia sa ale zatiaľ neplánuje predávať, vedci len skúšajú, ako by sa dali šošovky v budúcnosti používať. Bangladéš sa bojí o svoje tigre. Výskumníci totiž zistili, že v mangrovových lesoch sa ukrýva menšia populácia bengálskych tigrov, než sa úrady pôvodne domnievali. Problémom je aj malý počet samcov.
Welcome to another live episode at The AMR Studio! This time we are coming to you live from ECCMID2019, the annual European Congress of Clinical Microbiology and Infectious Diseases. We had the pleasure to interview 5 young researchers coming from around the globe (Australia, Norway, Spain, France & the USA) about their current projects and work. Listen to this episode to learn more antibiotic resistance transmission in cystic fibrosis patients; the characteristics of Mycobacterium abscessus; virulence in Acinetobacter baumannii; the user perception of antibiotic resistance; and rapid identification/antimicrobial susceptibility testing. Check relevant links and material at www.uac.uu.se/the-amr-studio/episodeX2/. Follow our updates on twitter on www.twitter.com/uac_uu with #theAMRstudio hashtag! Theme music by Henrik Niss: www.tinyurl.com/henriknissspotify.
Welcome to a new episode of The AMR Studio! This time, we have the interview we did with Dr. Coll De Lima Hutchison from the London School of Hygiene and Tropical Medicine. We chatted with him about his work in anthropology, and got a good insight into the importance of cultural and historical backgrounds when trying to change behaviours. In our news section we bring to you the latest research on the presence of antibiotic resistance genes in the environment, and the transmission of plasmids between bacteria. Check relevant links and material at www.uac.uu.se/the-amr-studio/episode4/. Follow our updates on twitter on www.twitter.com/uac_uu with #theAMRstudio hashtag! Theme music by Henrik Niss: www.tinyurl.com/henriknissspotify.
Enlouquecemos! Nesse episódio teremos não apenas um artigo na discussão principal mas teremos SEIS! Dessa vez pedimos para os alunos da disciplina Mecanismos Moleculares da Virulência Bacteriana, coordenada pelo Leandro, que fizessem uma análise de diferentes artigos sobre mecanismos de virulência bacteriana. E assim, eles se reuniram para mostrar as táticas de guerra que as bactérias patogênicas podem usar numa batalha contra nosso Sistema Imune, seus mecanismos de virulência. No Microlitros de Notícias, temos uma notícia beeemmm pequenininha sobre mini RNAs virais e também vamos descobrir como bactérias podem transformar você em um doador universal de sangue. A gente tem hoje uma entrevista com a Marcella do blog Tira o Jaleco. Tópicos comentados nesse episódio Mecanismos de virulência Bactérias patogênicas Aderência Evasão Invasão Mecanismos de secreção Toxinas Regulação gênica Mini RNAs virais Bactérias na alteração de tipo sanguíneo Acessem o site de nossos queridos colegas: Tira o Jaleco e História da Ciência Referências desse episódio 2018. Hiroya Oki, Kazuki Kawahara, Takahiro Maruno, Tomoya Imai, Yuki Muroga, Shunsuke Fukakusa, Takaki Iwashita, Yuji Kobayashi, Shigeaki Matsuda, Toshio Kodama, Tetsuya Iida, Takuya Yoshida, Tadayasu Ohkubo, and Shota Nakamura. Interplay of a secreted protein with type IVb pilus for efficient enterotoxigenic Escherichia coli colonization. PNAS. 2018. Quentin Bernard, Alexis A. Smith, Xiuli Yang, Juraj Koci, Shelby D. Foor, Sarah D. Cramer, Xuran Zhuang, Jennifer E. Dwyer, Yi-Pin Lin, Emmanuel F. Mongodin, Adriana Marques, John M. Leong, Juan Anguita, and Utpal Pal. Plasticity in early immune evasion strategies of a bacterial pathogen. PNAS. 2017. Sean P. Riley, Ludovic Pruneau, Juan J. Martinez. Evaluation of changes to the Rickettsia rickettsii transcriptome during mammalian infection. PLOS one. 2017. Nour-Imene Zahaf e Gudula Schmidt. Bacterial Toxins for Cancer Therapy. Toxins. 2018. Geisinger E, Mortman NJ, Vargas-Cuebas G1, Tai AK, Isberg RR. A global regulatory system links virulence and antibiotic resistance to envelope homeostasis in Acinetobacter baumannii. PLOS Pathogen. 2018. Cools F, Torfs E, Vanhoutte B, de Macedo MB, Bonofiglio L, Mollerach M, Maes L, Caljon G, Delputte P, Cappoen D, Cos P. Streptococcus pneumoniae galU gene mutation has a direct effect on biofilm growth, adherence and phagocytosis in vitro and pathogenicity in vivo. Oxford Academic. 2018. Aartjan J. W. te Velthuis, Joshua C. Long, David L. V. Bauer, Rebecca L. Y. Fan, Hui-Ling Yen, Jane Sharps, Jurre Y. Siegers, Marian J. Killip, Hollie French, Maria José Oliva-Martín, Richard E. Randall, Emmie de Wit, Debby van Riel, Leo L. M. Poon & Ervin Fodor. Mini viral RNAs act as innate immune agonists during influenza virus infection. Nature. 2018. Chelsea Whyte. Bacteria can be used to turn type A blood into universal type O. Sobre o Podcast Microbiando A ideia do Microbiando é discutir artigos científicos de ponta em todas as áreas da microbiologia e imunologia. Vamos utilizar uma linguagem bem acessível para destrinchar esses artigos para vocês, mas sem perder o rigor científico e analítico necessário para essa tarefa. Além de discutir artigos nós teremos o quadro Microlitros de Notícias, onde nossos microbiologistas e imunologistas de plantão irão abordar pequenas reportagens e trazer novidades para vocês. No quadro filogenia da Ciência vamos contar um pouco sobre a vida de grandes personalidades que revolucionaram a Microbiologia e Imunologia com suas descobertas. Você pode nos ouvir no Spotify, Google Podcast, Player FM, Podcast Addict, CastBox, Blubrry Podcasting, iTunes e outros agregadores de podcasts. Contatos E-mail: microbiando@micro.ufrj.br Twitter Facebook Instagram Expediente Produção Geral: Leandro Lobo Hosts: Leandro Lobo Equipe de Pauta/Gravação: Adriana Cabalas, Ana Carolina Oliveira,
In the fourth and final episode of the series, anthropologist and physician Omar Dewachi (American University of Beirut) discusses war as a form of governance, drawing on years of ethnographic research on the breakdown of health care in Iraq as well as the travelling wounds of injured Iraqi patients forced to seek medical treatment in other Middle Eastern countries. Dewachi traces the historical formation and effects of global discourses casting Iraq as ungovernable and connects the construction of Iraq as ungovernable to the emergence of the multi-drug resistant Acinetobacter baumannii. Dewachi offers fascinating insights into how war is fueling antimicrobial resistance and generative suggestions about the kinds of ethnographic objects that can help anthropologists talk about war without reproducing the distinction between the direct and indirect effects of war. Hosted by Vasiliki Touhouliotis and Emily Sogn, this four-part series on the “military present” features interviews with scholars of war and militarism that explore how our present is shaped by the technologies, logics, histories, and economy of war. In the first episode, Joe Masco (University of Chicago) spoke about the historical formation of an affective politics that creates a continuous, yet increasingly incoherent militarization, justifying itself as a response to a panoply of perceived threats. In the second episode, Madiha Tahir (Columbia University) discussed how new weapons technologies, particularly drones, have reshaped social landscapes in places like the Waziristan region of Pakistan, where threats both in the air and on the ground, have become an ever-present fact of everyday life. In the third episode, Wazmah Osman (Temple University) spoke about the embodied effects of war in Afghanistan and illustrated how the language of newness and precision are deployed to obscure the long-term and everyday damage caused by ongoing war. For a full transcript of this episode, please follow this link: http://www.americananthropologist.org/the-military-present-episode-4-transcript/ Credits: P.J. Harvey "The Glorious Land" (www.youtube.com/watch?v=h1lFM1K8R1s) Image Caption: Berm remains at Fao, Iraq, the site of one of the bloodiest battles of the Iran Iraq-war (1980-1988). Photograph taken by Omar Dewachi(2015).
Dave Rasko uses comparative bacterial genomics to find DNA sequences that influence virulence or antibiotic resistance. Dave talks about his studies of E. coli, Acinetobacter baumanii, and B. anthracis, and the state of bacterial genomics past, present, and future. Host: Julie Wolf Subscribe (free) on iPhone, Android, RSS, or by email. You can also listen on your mobile device with the ASM Podcast app. Julie's biggest takeaways: Genome sequencing speed has significantly increased: The first bacterial genome sequenced, Haemophilus influenzae, took about 10 years to complete. The first organism with two sequenced genomes was Helicobacter pylori, published in 1999, and the first organism with three published genomes was Escherichia coli. Rasko’s initial project at TIGR to sequence 11 E. coli genomes took about 2 years. Today, Rasko’s lab can sequence 500 genomes in about five days. In E. coli, up to half of the genome can differ between two strains. The core genome is the collection of genes that will be shared among all isolates of a particular species. Core gene conservation varies among species and is important to consider in analyses for one’s species of interest. Working on the Amerithrax investigation was unlike many other scientific inquiries for many reasons, including that the Federal Bureau of Investigation only gave the scientists involved the information pieces necessary to conduct their studies. Rasko and collaborators sequenced the genomes of spores within the samples, and found that the morphology of the colonies that grew were associated with genetic differences between the spores within the sample, linking phenotype and genotype. While comparative genomics can provide a lot of information, there are some phenomena that will always require further study. For example, Rasko is researching isolates of A. baumanii and Klebiella pneumoniae that quickly develop drug resistance when grown in sub-inhibitory drug concentrations. The genomic sequences of resistant or susceptible strains show no difference in DNA sequence, suggesting the phenotype is due to transcriptional changes. Featured Quotes (in order of appearance) “Genomics is fun in that we can hypothesize all day long, every day. It’s really the start of a lot of very very hard work figuring out why.” “There’s a lot of DNA pieces that we don’t fully understand how they moved, where they moved, where they came from. In some cases, there’s evidence to say where they came from; in terms of G-C content and coding biases, we can make some assumptions, but in the grand scheme of things, we have no idea where they’re coming from! In some cases, we’ll see them dominant throughout a lineage, and in some cases we’ll see them in sporadic isolates around the entire phylogenetic tree. . .We all thought genomics was going to solve so many problems, and it’s really just made it more difficult!” “Plasmids tend to be mobile and exchangeable, and the pieces tend to be - I tend to think of them as legos, in the fact that you can put a plasmid together in a bunch of different ways.” “I think a lot of conventional PCR fails and people assume that it’s because it’s negative, and not necessarily that it fails because of diversity.” “Many microbiologists think of that colony on a plate as a clone. I force the people in my group to think about it a little differently, because it’s really what I like to call ‘genome space’. They’re not all the same; bacteria are constantly evolving. There’s changes all the time, some of them are positive, some of the are negative, the negative ones get lost, the positive ones unusually become dominant - and then there’s lots of neutral changes that just kind of hang out.” “Genomes really normalized everything. Before that, there were certain labs that could clone and there were certain labs that could sequence, and it was a little bit restrictive to the elite labs who had those resources. Now with the genome sequences out there, everyone was starting from the same place.” “You really have to understand your organism to make the bioinformatics work.” Links for this episode Rasko lab at the University of Maryland FBI summary of Amerithrax investigation 2011 PNAS report on B. anthracis comparative genomics Bugs N the ‘hood HOM Tidbit: Stanley Falkow gives both video history and written history of plasmid biology Save on Microbe 2018, use code: asmpod Send your stories about our guests and/or your comments to jwolf@asmusa.org.
Esta semana hablamos del resultado del Estudio AIDA, que busco evaluar el uso de colistina versus la combinación de colistina y meropenem en el tratamiento de infecciones por gérmenes Gram-negativos resistentes a carbapenemicos, pero cuyos resultados, como explicaremos, son básicamente relevantes para el caso de infecciones por Acinetobacter sp. resistentes a carbapenemicos. Referencias: Mical Paul y colaboradores. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. Feb 15, 2018. Frase de la Semana: Recurrimos nuevamente a Mark Twain para la frase de esta semana. Escritor, humorista, empresario, editor y conferencista estadounidense. Entre sus novelas se encuentran Las aventuras de Tom Sawyer (1876) y su secuela, Las aventuras de Huckleberry Finn (1885), esta última a menudo llamada "La gran novela estadounidense". “Es más fácil engañar a la gente que convencerlos de que han sido engañados”.
Join Kara Mullane as she reads two selected AJIC Abstracts from Journal Oct 2017, Vol 45, No 10. Topics: Prospective clinical trial to assess peripheral venous catheter-related phlebitis using needleless connectors in a surgery department; Outbreak of imipenem-resistant Acinetobacter baumannii in different wards at a regional hospital related to untrained bedside caregivers. Subscribe and never miss and episode!
Bacteriophages are viruses that infect and kill bacteria. When they were first discovered in the early part of the 20th century, there was great enthusiasm for their potential use to treat all sorts of bacterial infections. They were supplanted by antibiotics and although they remained critically important in research that led to the understanding of DNA and how it works, bacteriophages never really made it in the therapeutic world. Now that multiple-drug-resistant bacteria are becoming increasingly common, there is renewed interest in using bacteriophages to treat bacterial infection. Links: YouTube video summarizing the career and science of Félix d'Hérelle-one of the discoverers of bacteriophages Dr. Felix d'Herelle Canadian Medical Hall of Fame Laureate 2007 Detailed history of the development of bacteriophage research in Georgia A Stalinist Antibiotic Alternative from New York Times Magazine, February 6, 2000 Reprint of Twort’s initial description of a substance killing bacteria discovered while trying to grow viruses. Although Twort did not identify bacteriophages in his experiment, he believed there was some toxic entity that killed bacteria present in his experiments. An investigation on the nature of ultra-microscopic viruses1 by Twort FW, L.R.C.P. Lond., M.R.C.S. Reprint and translation of d’Herelle’s original 1917 description of bacteriophages isolated from soldiers recovering from dysentery. On an invisible microbe antagonistic to dysentery bacilli. Note by M. F. d’Herelle, presented by M. Roux. Comptes Rendus Academie des Sciences 1917; 165:373–5 Review of the non-English-language literature on bacteriophage therapy of infection Bacteriophage Therapy Antimicrob Agents Chemother. 2001 Mar; 45(3): 649–659. Review of the history bacteriophage research and its effect on scientific development and clinical medicine The Murky Origin of Snow White and Her T-Even Dwarfs Genetics 155: 481–486 (June 2000) News report from UC San Diego on treatment of the patient described in the podcast Novel Phage Therapy Saves Patient with Multidrug-Resistant Bacterial Infection 2017 JAMA Medical News article on the use of bacteriophage to treat a patient with multidrug-resistant Acinetobacter infection Phage Therapy’s Role in Combating Antibiotic-Resistant Pathogens
In this interview from the Outbreak News This Week Radio Show in May 2017, we looked at this amazing story of an individual with a multi-drug resistant Acinetobacter baumannii infection and the use of an experimental therapy involving bacteriophages — viruses that target and consume specific strains of bacteria. Case study lead author and the primary physician of the patient, Professor of Medicine and Chief of the Division of Infectious Diseases at the UC San Diego School of Medicine, Robert Schooley,MD joined me to share the details of the remarkable story.
Coming up on Biotechnology Focus Radio: The launch of a new Canadian Regenerative Medicine Alliance, Canada’s House of Commons passes the Genetic Discrimination Act Bill S-201, and a One-Two Punch that May Floor the Worst Infections by stopping antibiotic drug resistance. Welcome to another episode of Biotechnology Focus Radio. I’m your host Shawn Lawrence, here to give you a rundown of this week’s top stories on the Canadian biotech scene. Our first story this week takes us to Toronto, where Antibe Therapeutics Inc. reports it has signed an exclusive licensing and distribution agreement with a pharmaceutical company, Laboratories Acbel SA (Acbel), for its lead product ATB-346. ATB-346 is an anti-inflammatory drug, designed to spare the gastrointestinal tract of the ulcers and bleeding normally associated with NSAIDs. The agreement covers distribution in Greece, Romania, Serbia, Bulgaria, Albania, Algeria and Jordan. Antibe will receive an upfront, non-dilutive payment of $1.1 million, and is entitled to receive a 5 per cent royalty on net sales of ATB-346 in these countries. The agreement has a 30-year term with contemplated renewals thereafter. Acbel, through its affiliates and partners, is the largest seller of naproxen in this region, which represents approximately one per cent of the global market for nonsteroidal anti-inflammatory drugs (NSAIDs). The global market for NSAIDs is in excess of US$12 billion (Evaluate Pharma). In a recent Phase 2 clinical trial, ATB-346 was found to be highly effective in reducing the pain associated with osteoarthritis of the knee. Antibe says it will now initiate two larger Phase 2 double-blind trials: a placebo-controlled dose-ranging study to determine the go-to-market dose, and an active comparator trial to demonstrate superior GI safety. Antibe also has two other therapeutic candidates in development: ATB-352 and ATB-340. ATB-352 is a non-addictive analgesic for treating severe acute pain and ATB-340 is a GI-safe derivative of aspirin. Antibe intends to leverage data across its programs to secure licensing agreements whenever possible. In regulatory news Canada’s House of Commons has passed Bill S-201 (An Act to Prohibit and Prevent Genetic Discrimination in Canada), as it was presented, by the Standing Committee on Justice and Human Rights on Wednesday March 8, 2017. According to Bev Heim-Myers, chair of the Coalition for Genetic Fairness and CEO of the Huntington Society of Canada (HSC), while the Bill will still have to go to the Senate, all indications point to it being fully supported. Heim-Myers adds that Canada has finally caught up to other western jurisdictions in regards to protection of genetic information and Canadian legislation has caught up to science. Since the Genome Project was launched in the early 1990s, Canada had been the only G7 country that had not taken steps to prevent genetic discrimination. With this decision, this changes. Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to “reboot” the body’s innate immune system, has reported positive genetic analyses of their recently completed Phase 2 clinical studies in Crohn’s Disease (CD) and Ulcerative Colitis (UC). These findings suggest that, for the first time in the field of inflammatory bowel disease (IBD), personalized medicine and the application of genetic testing may identify patients highly likely to respond and go into remission with treatment. The analyses identified common IBD-related genotypes with a high likelihood of response to SSI, suggesting that genetic testing may identify a large subset of CD patients (representing approximately 60% of the CD population) with a greater than 80% likelihood of responding to QBECO treatment, the large majority of which achieved remission on SSI treatment. Dr. Hal Gunn, CEO of Qu Biologics, stated, “We are very excited about the possibility of identifying CD and UC patients highly likely to respond to SSI treatment, which would substantially de-risk future trials and be an important advance for patients who currently face the uncertainty of knowing whether current immunosuppressive IBD treatments, which can be associated with significant side effects, will work for them or not.” Dr. Shirin Kalyan, Qu’s Director of Scientific Innovation, added, “Unlike current IBD treatments that suppress immune function, we believe that SSIs, which restore innate immune function, treat the underlying cause of IBD. Consequently, unlike other treatments, we were able to identify IBD-related genotypes highly responsive to SSI therapy. It is exciting that the genotypes correlated with SSI response are highly relevant to SSIs’ mechanism of action.” Based on the promising results of Qu Biologics’ recently completed Phase 2 study in CD, a follow-on Phase 2 study in moderate to severe CD is planned to confirm these findings. Study initiation is anticipated in late 2017. If the genetic analysis results are confirmed in follow-on studies, Qu Biologics’ QBECO SSI has the potential to become first-line therapy for a majority of IBD patients. In funding news, the Federal Economic Development Agency for Southern Ontario (FedDev Ontario) is providing TechAlliance of Southwestern Ontario with up to $1.32 million to deliver on a new incubation program, called BURST, which will provide 30 innovative technology entrepreneurs in southwestern Ontario with mentoring and business guidance, seed funding, exposure to potential investors and access to a dedicated working space in Western University's Discovery Park. As entrepreneurs establish and grow their businesses with help from this program, it is expected that up to 45 new full-time jobs will be created. Building on London's history of innovation in health sciences, a unique partnership with the London Medical Network will also be established to help eligible medical technology companies receive funding. The announcement was made on behalf of the Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development and Minister responsible for FedDev Ontario. In Hamilton, ON, McMaster University researchers say they have found a new way to treat the world’s worst infectious diseases, the superbugs that are resistant to all known antibiotics. The McMaster team published their findings in the journal Nature Microbiology last week. Eric Brown, senior author of the paper, a professor of biochemistry and biomedical science at McMaster’s Michael G. DeGroote School of Medicine and a scientist of the Michael G. DeGroote Institute for infectious Disease Research says his team looked for compounds that would mess with these antibiotic resistant bacteria, focusing on Gram-negative bacteria which are resistant to all antibiotics including last resort drugs, such as colistin, and lead to pneumonia, wound or surgical site and bloodstream infections, as well as meningitis in healthcare settings. Brown explains that Gram-negative bacteria have an intrinsically impenetrable outer shell that is a barrier to many otherwise effective antibiotics, and this makes these infections deadly, particularly in hospital settings. His team tested a collection of 1,440 off-patent drugs in search of one that might compromise that barrier in the superbugs. “These pathogens are really hard nuts to crack, but we found a molecule that shreds that shell and allows antibiotics to enter and be effective,” Brown said. The scientists discovered the antiprotozoal drug pentamidine disrupts the cell surface of Gram-negative bacteria, even the most resistant. The anti-fungal medication was particularly potent when used with antibiotics against multidrug resistant bacteria. Moreover, Pentamidine, when used with other antibiotics, was found to be particularly effective against two of the three pathogens which the WHO has identified as having the most critical priority for development of new antibiotics. Those were Acinetobacter baumannii and the enterobacteriaceae. The combo therapy also had some impact on the third most critical bacteria, Pseudomonas aeruginosa according to Brown. Brown continued saying These discoveries were found to be effective in the lab and in mice, but more work is needed to offset potential side effects and ensure human safety. Brown adds that his lab is continuing to test more compounds as well. “One of the things we want to pursue further is why this is working so well,” he said. The study was supported by grants from the Canadian Institutes of Health Research, the National Sciences and Engineering Research Council and Cystic Fibrosis Canada, among others. http://bit.ly/2m3hZq2 In our final story , a group of Canadian Stem Cell & Regenerative Medicine Leaders have announced that they are Joining Forces to Advance Canada’s Position in the Field, with the launch late last week of a new national group called the Regenerative Medicine Alliance of Canada. The founding members include: CCRM; The Centre for Drug Research and Development (CDRD); CellCan; Medicine by Design; Ontario Institute for Regenerative Medicine; ThéCell; Canadian Stem Cell Foundation, and Stem Cell Network. The goal of this new Regenerative Medicine Alliance of Canada or (RMAC) will be to advance Canada’s stem cell science and regenerative medicine sector by aligning national activity in the field. Its members say they plan to work collaboratively to share information and identify strategies that will benefit the growth of Canada’s regenerative medice expertise. The initial concept for this alliance was conceived by members of the regenerative medicine community during a workshop on the state of regenerative medicine in Canada. The workshop was held by the Council of Canadian Academies in 2016. Their newly released report notes the importance of strategic coordination amongst the stem cell and regenerative medicine community. Bolstering and aligning programs, training, policy and communication will also be central themes addressed by RMAC. According to the Alliance, With the global market for regenerative medicine iexpected to exceed US$49 billion by 2021, the need to keep Canada well positioned to compete by moving its innovative treatments and therapies out of the lab and into the clinic has never been greater. Countries around the world, including the U.S., Japan and the U.K., have already taken bold steps through investment and regulatory modernization to capture a significant piece of the market. RMAC will serve as a mechanism to support strategic activity across the regenerative medicine sector in Canada. The RMAC will act voluntary organization comprised of national, provincial and regional organizations. All members have mandates relevant to stem cell research and/or regenerative medicine. Well that wraps up another episode of the Biotechnology Focus Podcast. We hope you enjoyed it. Be sure to let us know what you think, and we’re also always looking for story ideas and suggestions for future shows, and of course we’d love to hear from you as well, simply reach out to us via twitter @biotechfocus, or by email at the following email address press@promotivemedia.ca. And
The TWiM team brings you a bacterium from a Colorado field site that grows on uranium, and copper resistance in the emerging pathogen Acinetobacter baumannii. Hosts: Vincent Racaniello, Michael Schmidt, Elio Schaechter, and Michele Swanson. Subscribe to TWiM (free) on iTunes, Stitcher, RSS, or by email. You can also listen on your mobile device with the Microbeworld app. Links for this episode Kavli Microbiome Ideas Challenge Uranium-respiring bacterium from a field site (PLoS One) Acid mine drainage (Wikipedia) Copper resistance of Acinetobacter baumannii ASM Grant Writing Online Course TWiM #132: Bacteria learn long division Image credit This episode is brought to you by CuriosityStream, a subscription streaming service that offers over 1,400 documentaries and nonfiction series from the world's best filmmakers. Get unlimited access starting at just $2.99 a month, and for our audience, the first two months are completely free if you sign up at curiositystream.com/microbe and use the promo code MICROBE. This episode is also brought to you by Drobo, a family of safe, expandable, yet simple to use storage arrays. Drobos are designed to protect your important data forever. Visit www.drobo.com to learn more. Listeners can save $100 on a Drobo system at drobostore.com by using the discount code Microbe100. Send your microbiology questions and comments (email or mp3 file) to twim@microbe.tv
Vincent, Elio, and Michael consider a fungal pathogen of insects that acquired a gene from its host that facilitates infection, and presence of gram-negative nosocomial pathogens on community surfaces near hospitals in Brooklyn.
El Radioscopio 55 - Fri, 24/05/2013 Invitado: Michael J. McConnell - Instituto de Biomedicina de Sevilla Contenido:Fin de la saga "¿Hay un investigador a bordo? - Acinetobacter Te presentamos a Acinobacter Baumanii, uno de los especímenes más peligrosos que pululan por nuestros hospitales. Y además, el fin de una saga épica: ¿Hay un científico a bordo?
Dr. Catherine Noakes, PhD, CEng is the Director of Pathogen Control Engineering Institute at the School of Civil Engineering, University of Leeds. She is also the Leader of Aerobiology and Infection Control Research Group at the University of Leeds. The Aerobiology and Infection Control Group is a multi-disciplinary research team comprising microbiologists, engineers and mathematical modelers. The group has considerable experience in evaluating bioaerosols in indoor environments and engineering measures to control infection. Their Research is driven by the continuing problem of hospital acquired infection and the worldwide health concerns about infectious diseases spread through airborne routes. Airborne transmission is known to be a primary mechanism in the transmission of TB and influenza, but has also been implicated in the transmission of nosocomial infections including MRSA, Acinetobacter spp, C. difficile and norovirus. In addition, contamination of the environment through contact with dirty hands and objects or airborne dispersal provides a potential reservoir of pathogens which could subsequently cause infection by indirect contacts. Regardless of the pathogen, successful control of infection involves breaking the chain of transmission, for which it is necessary to understand both the mode of transmission as well as the nature of the pathogen and its behavior in the environment. Understanding this complex interaction between people, pathogens and the built environment is at the heart of their research. The paper that prompted the press interest is work carried out by Marco-Felipe King, one of my PhD students, stated Dr. Noakes. His overall project is trying to determine whether single rooms in hospitals present a lower infection risk than multi-bed rooms. This is something that is quite often stated and for which there is anecdotal evidence, but isn't quantified. He is trying to quantify the difference in risk between the two types of rooms for infection spread due to environmental contamination. This paper presents the first part of this work where he was looking to quantify surface contamination due to an aerosol source and validate the techniques for modeling it. This is feeding into the next stage of the research where he is using the ability to predict contamination on a surface together with a mathematical model for a nurse moving around a ward and touching surfaces to compare the potential for contamination.
Dr. Catherine Noakes, PhD, CEng is the Director of Pathogen Control Engineering Institute at the School of Civil Engineering, University of Leeds. She is also the Leader of Aerobiology and Infection Control Research Group at the University of Leeds. The Aerobiology and Infection Control Group is a multi-disciplinary research team comprising microbiologists, engineers and mathematical modelers. The group has considerable experience in evaluating bioaerosols in indoor environments and engineering measures to control infection. Their Research is driven by the continuing problem of hospital acquired infection and the worldwide health concerns about infectious diseases spread through airborne routes. Airborne transmission is known to be a primary mechanism in the transmission of TB and influenza, but has also been implicated in the transmission of nosocomial infections including MRSA, Acinetobacter spp, C. difficile and norovirus. In addition, contamination of the environment through contact with dirty hands and objects or airborne dispersal provides a potential reservoir of pathogens which could subsequently cause infection by indirect contacts. Regardless of the pathogen, successful control of infection involves breaking the chain of transmission, for which it is necessary to understand both the mode of transmission as well as the nature of the pathogen and its behavior in the environment. Understanding this complex interaction between people, pathogens and the built environment is at the heart of their research. The paper that prompted the press interest is work carried out by Marco-Felipe King, one of my PhD students, stated Dr. Noakes. His overall project is trying to determine whether single rooms in hospitals present a lower infection risk than multi-bed rooms. This is something that is quite often stated and for which there is anecdotal evidence, but isn't quantified. He is trying to quantify the difference in risk between the two types of rooms for infection spread due to environmental contamination. This paper presents the first part of this work where he was looking to quantify surface contamination due to an aerosol source and validate the techniques for modeling it. This is feeding into the next stage of the research where he is using the ability to predict contamination on a surface together with a mathematical model for a nurse moving around a ward and touching surfaces to compare the potential for contamination.
Internationale Experten fuer Infektionskontrolle warnen vor einer zunehmenden weltweiten Bedrohung durch das Bakterium Acinetobacter baumannii. Der Hygieneexperte Dr. Oskar Janata, Oberarzt im Donauspital in Wien, stellt die aktuelle Situation fuer Oesterreich dar.
John McConnell discusses commercial assays for C difficile diagnosis, antimicrobial catheters, and Acinetobacter baumannii.
Guest: Arjun Srinivasan, MD Host: Shira Johnson, MD Dr. Shira Johnson interviews Dr. Arjun Srinivasan, who is a Medical Epidemiologist from the CDC in Atlanta. His work is to diagnose and to prevent outbreaks of infections in the hospital and in the community. Learn about a resistant infection caused by Acinetobacter which is prolonging ICU stays across the country. Acinetobacter species has become increasingly difficult to treat due to the development of antibiotic resistance, and mortality and length of hospitalization are increased in a subset of patients.
© 2020-2025 Ivy Podcast Discovery LLC
